Oncology & Cancer

Positive results for phase 1 trial of ivosidenib against AML

Early phase clinical trial results presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 of 258 patients with IDH1+ acute myeloid leukemia (AML) treated with the IDH1 inhibitor ivosidenib ...

Oncology & Cancer

Targeted cancer treatments far outperform traditional methods

Cancer treatments that attack tumors based on their individual genetic traits—not their location in the body—far outperform traditional methods, extending survival for twice as many patients, a study said Saturday.

Oncology & Cancer

After 40 years in limbo: Styrene is probably carcinogenic

For 40 years, researchers have believed there is an increased risk of cancer associated with styrene. Now, a working group under the auspices of the WHO and appointed by the International Agency for Research on Cancer (IARC), ...

Oncology & Cancer

New potential target identified to fight acute myeloid leukemia

AML is not a single disease. It is a group of leukemias that develop in the bone marrow from progenitors of specialized blood cells, the so-called myeloid cells. Rapidly growing and dividing, these aberrant cells crowd the ...

page 39 from 40